Blow To Ipsen As FerGene Nabs CEO Meek
Bad Timing For French Firm
Executive Summary
The new Ferring-backed gene therapy company has bagged a big name player in David Meek as its CEO but the move has created a void at the top for France's Ipsen.
You may also be interested in...
How The Curtain Finally Closed On Ferring/Blackstone’s Gene Therapy Venture FerGene
Having failed to live up to its promising beginnings, FerGene, the gene therapy firm founded with the backing of Ferring and Blackstone to advance the former’s candidate for bladder cancer is back under the Swiss pharma's wing. However, doubts about its future and that of nadofaragene firadonavec remain.
Mirati’s Adagrasib Takes The Lead Among KRAS G12C Inhibitors In CRC
Adagrasib may carve out a niche as the superior drug in colorectal cancer, but lung cancer – where Lumakras already is approved – is a larger market where Amgen has a big lead.
Ipsen’s Dysport Likely Impacted By COVID-19 In Q2, But China Sales To Return
Sales grew 9.6% at Ipsen in the first quarter, and the search for a new CEO is on track, but France’s specialty pharmaceutical company maintained its 2020 guidance suspension because of the uncertainty over the course of the COVID-19 pandemic.